Literature DB >> 11872915

Emergent use of anticoagulation for treatment of patients with ischemic stroke.

Harold P Adams1.   

Abstract

BACKGROUND: Several clinical trials have tested the potential utility of emergent anticoagulation for acute ischemic stroke. SUMMARY OF REVIEW: Rather than performing a meta-analysis that combines the data from several trials, this review focuses on individual studies. Although these trials do have inherent limitations, they demonstrate that emergent use of an anticoagulant is associated with a modest but significantly increased risk of hemorrhagic transformation of the ischemic stroke or serious nonneurological bleeding. The trials do not demonstrate a benefit from emergent anticoagulation in improving outcome, reducing mortality, and preventing early recurrent stroke.
CONCLUSIONS: These results suggest that most patients with acute stroke should not be treated with unfractionated heparin or other rapidly acting anticoagulants after stroke. Prevention of deep vein thrombosis and pulmonary embolism among bedridden patients is the only established indication for early anticoagulation after acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872915     DOI: 10.1161/hs0302.104628

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

Review 1.  Hemorrhagic transformation after cerebral infarction: current concepts and challenges.

Authors:  Jie Zhang; Yi Yang; Huijie Sun; Yingqi Xing
Journal:  Ann Transl Med       Date:  2014-08

2.  Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.

Authors:  Jae-Kwan Cha; Min-Ho Jeong; Kyung-Mi Lee; Hae-Rahn Bae; Yeong-Jin Lim; Kyung Won Park; Sang-Myung Cheon
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

Review 3.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

4.  Isolated middle cerebral artery disease: clinical and neuroradiological features depending on the pathogenesis.

Authors:  P H Lee; S H Oh; O Y Bang; I S Joo; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 5.  Secondary prevention of stroke: a practical guide to drug treatment.

Authors:  H-C Koennecke
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Pulmonary embolism after brain hemorrhage in a hypertensive patient: the therapeutic dilemma.

Authors:  Carlo Oneglia; Anna Gualeni
Journal:  J Thromb Thrombolysis       Date:  2007-05-30       Impact factor: 2.300

7.  The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.

Authors:  E J Su; M Geyer; M Wahl; K Mann; D Ginsburg; H Brohmann; K U Petersen; D A Lawrence
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

8.  Retrospective study of Heparin Administration for Ischemic Stroke when there is an IV-tPA Contraindication.

Authors:  Zakaria Hakma; Douglas L Stofko; Mandy Jo Binning; Kenneth Liebman; Erol Veznedaroglu
Journal:  Surg Neurol Int       Date:  2014-05-06

9.  Anticoagulant therapy for ischemic stroke: A review of literature.

Authors:  Mohammad Mehdi Shahpouri; Seyed Mousavi; Faribourz Khorvash; Seyed Morteza Mousavi; Tahereh Hoseini
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

Review 10.  Stroke pathophysiology: management challenges and new treatment advances.

Authors:  J Jordán; I Ikuta; J García-García; S Calleja; T Segura
Journal:  J Physiol Biochem       Date:  2007-09       Impact factor: 5.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.